Industry Press Releases

Applied BioCode Receives CE Mark Certification for BioCode® MDx 3000 with 18-plex Gastrointestinal Pathogen Panel

Tuesday, Apr 24, 2018

Applied BioCode announced today that they have received CE mark certification for the BioCode® MDx 3000 with 18-plex Gastrointestinal Pathogen Panel. This will allow commercial distribution of the first MDx 3000 systems in Europe as well as in all countries recognizing the CE mark.

“We are extremely pleased to receive the CE mark certification for our BioCode® MDx 3000 system with 18-plex Gastrointestinal Pathogen Panel,” said Winston Ho Ph.D. “Our system will help hospitals and clinical laboratories to provide high volume syndromic testing to their patients at a more affordable cost. The GI Pathogen Panel is the first of many syndromic panels we expect to bring to our customers.”

The BioCode® MDx 3000 utilizes proprietary Barcoded Magnetic Beads and automates the PCR amplification, hybridization/ target capture and detection processes of molecular diagnostic testing. The system can process up to 94 samples in about 3.5 hours, or up to 3,384 results in an 8-hour shift. The automated system was designed to reduce hands-on time, maximize test throughput, and minimize the potential for sample contamination. It has the ability to process up to 3 different assay panels on the same run and provides the capability to automatically mask any test results within individual panels for tests not ordered on the patient. Based on the 96-well microplate, the system offers both throughput advantages and cost savings compared to cartridge-based systems. The MDx 3000 system also offers a User Defined Mode where laboratories can develop their own multiplex assays to run on the system.

The BioCode® 18-plex Gastrointestinal Pathogen Panel (GPP) includes the most common pathogenic bacteria, viruses, and parasites. The BioCode® GPP includes targets for the bacteria (Campylobacter, Clostridium difficile toxin A&B, Salmonella, Shigella, Shiga toxin producing E.coli, E. coli O157, Enterotoxigenic E.coli, Enteropathogenic E. coli, Enteroaggregative E. coli, Vibrio parahaemolyticus, Vibrio spp., (Vibrio vulnificus, Vibrio cholerae), Yersinia enterocolitica), viruses (norovirus group I/II, adenovirus 40/41, rotavirus A), and parasites (Giardia, Cryptosporidium, Entamoeba histolytica).

About Applied BioCode

Applied BioCode is a publicly traded diagnostic company that develops, manufactures, and markets Barcoded Magnetic Beads (BMBs) and detection systems to facilitate development of highly multiplexed nucleic acids or protein detection assays. The BMB technology offers up to 4,096 unique digital barcodes for multiplex analysis with unmatched decoding accuracy. Our easy-to-use BioCode® systems employ steady state detection without requiring flow cytometers that are prone to channel blockage or sample cross contamination. The system is well suited for clinical diagnostic applications such as detection of pathogens, drug resistance markers, cancer markers & mutation analysis, as well as specific applications for the life science research and agricultural testing markets. For more information, please visit the company’s website at www.apbiocode.com.

Contacts
Applied BioCode
Dr. Winston Z. Ho
President
+1 (562) 801-0050

 

Source: businesswire.com

Other Press Releases